Loading...
Overall survival (OS) has improved for patients with metastatic colorectal cancer (CRC) since the advent of more-effective systemic chemotherapy and agents targeting the vascular endothelial growth factor receptor (VEGFr) and epidermal growth factor receptor (EGFr) pathways. Although the EGFr agents cetuximab and panitumumab benefit only RAS wild-type tumors, similar benefits are seen for bevacizumab regardless of RAS status. However, the optimal sequencing of these agents in the treatment of RAS wild-type metastatic CRC has not been clearly established.
European investigators now report results of the phase III, randomized, open-label FIRE-3 trial, comparing first-line treatment of exon 2 KRAS wild-type CRC with FOLFIRI (irinotecan, leucovo…